U.S. markets open in 8 hours 21 minutes

C4 Therapeutics, Inc. (CCCC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.12+0.43 (+4.95%)
At close: 04:00PM EDT
9.57 +0.45 (+4.93%)
After hours: 04:44PM EDT

C4 Therapeutics, Inc.

490 Arsenal Way
Suite 200
Watertown, MA 02472
United States
617 231 0700

Full Time Employees121

Key Executives

NameTitlePayExercisedYear Born
Mr. Andrew J. HirschCEO, Pres & Director952.2kN/A1971
Dr. Kenneth C. Anderson M.D., Ph.D.Co-Founder, Independent Director & Member of Scientific Advisory Board35kN/A1951
Ms. Lauren A. WhiteChief Financial Officer546.34kN/AN/A
Dr. Stewart FisherChief Scientific Officer694.7k1.02M1967
Ms. Jolie M. Siegel J.D.Chief Legal Officer610.4k1.06M1977
Dr. Adam S. Crystal M.D., Ph.D.Chief Medical Officer701.7k2.63M1977
Dr. Nathanael S. Gray Ph.D.Co-Founder & Member of Scientific Advisory BoardN/AN/AN/A
Ms. Kendra AdamsSr. VP of Communications & Investor RelationsN/AN/AN/A
Kristina ZambourasDirector of HRN/AN/AN/A
Ms. Kelly SchickChief People OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Corporate Governance

C4 Therapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 8. The pillar scores are Audit: 3; Board: 9; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.